We deliver medicines worldwide · +91 92588 88880
Ponatinib 45mg Tablet
CANCER MEDICATIONS

Ponatinib 45mg Tablet

Genuine medicine sourced in India and shipped to your door worldwide. Message us for today’s price, stock and delivery time to your country.

Price on request Reply on WhatsApp, usually within an hour
  • Genuine medicineSourced from licensed suppliers
  • Worldwide deliveryDHL, FedEx, EMS & UPS
  • Cold chain shippingTemperature-safe handling
  • Customs paperwork doneFull legal documentation

About this medicine

Ponatinib 45mg Tablet: Uses in CML & Ph+ ALL, How It Works, Side Effects and Safety

When chronic myeloid leukaemia (CML) stops responding to first- and second-line treatment, patients and families can feel they’ve run out of options. Ponatinib 45mg Tablet was developed for exactly this situation. It is a targeted therapy for some of the hardest-to-treat forms of blood cancer.

What Is Ponatinib 45mg?

Ponatinib is a prescription cancer medicine known as a third-generation tyrosine kinase inhibitor (TKI). Its original brand name is Iclusig, and generic ponatinib tablets offer a more affordable option with the same active ingredient. Each film-coated tablet contains 45 mg of ponatinib and is taken by mouth.

What Is Ponatinib Used For?

Oncologists prescribe ponatinib for adults with:

  • Chronic myeloid leukaemia (CML): in the chronic, accelerated or blast phase, when other TKIs such as imatinib, dasatinib or nilotinib have stopped working or can’t be tolerated
  • T315I-positive CML: a mutation that makes the cancer resistant to almost every other TKI
  • Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL): including T315I-positive disease

Ponatinib is not recommended for newly diagnosed chronic-phase CML.

How Does Ponatinib Work?

CML and Ph+ ALL are driven by an abnormal protein called BCR-ABL. It acts like a stuck “on” switch that tells leukaemia cells to keep multiplying. Older TKIs block this switch, but over time the cancer can mutate and slip past them. The T315I mutation is the best-known example. Ponatinib was designed to fit the BCR-ABL protein even when it carries these mutations. That’s why it’s often called the T315I-active TKI.

How Is It Taken?

Ponatinib is taken once a day, with or without food, and the tablet is swallowed whole. Doctors often lower the dose once the leukaemia responds well, to reduce the risk of side effects. Follow your haematologist’s instructions exactly, and never change the dose on your own.

Common Side Effects

  • Rash and dry skin
  • Stomach pain, constipation or nausea
  • Headache and tiredness
  • Joint and muscle pain
  • High blood pressure
  • Low blood counts

Serious Risks to Know About

Ponatinib carries important safety warnings, so close monitoring is essential:

  • Blood clots and blocked arteries: these can lead to heart attack, stroke or reduced blood flow to the legs. The risk is higher in people with existing heart disease, diabetes or high cholesterol.
  • Heart failure: report breathlessness, swelling or a fast heartbeat straight away.
  • Liver problems: regular liver tests are needed.
  • Other monitoring: your doctor will check blood counts, blood pressure and pancreas enzymes regularly.

Before starting, tell your doctor about any heart, liver or blood-vessel problems and any medicines you take. Ponatinib may harm an unborn baby, so use effective contraception and avoid breastfeeding during treatment.

Storage

Store ponatinib tablets at room temperature in the original pack, away from moisture and out of reach of children.

Final Word

Ponatinib 45mg gives new hope to people with resistant or T315I-positive CML and Ph+ ALL when other treatments have failed. Buy only from a licensed pharmacy, and use it under the close care of an experienced haematologist or oncologist.

This information is for general reference only. Please use this medicine only under the guidance of your doctor, and share your prescription with us when you order.

More Cancer Medications

View all ›
Clients feedback

What our customers say

See all feedback →